Physician profile
James Cain
NPI 1174615868
$4,763.93
in general payments reported to CMS, 2019-2025
38 companies · $91.19 in 2025
The $91.19 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $267 · 2021: $909 · 2022: $823 · 2023: $1,230 · 2024: $1,114 · 2025: $91.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $708.55 | 2019-2023 | Krystexxa, Tepezza |
| Amgen INC. | $530.97 | 2019-2024 | Krystexxa, Tavneos, Tepezza |
| Astrazeneca Pharmaceuticals Lp | $396.85 | 2019-2024 | Farxiga, Lokelma, Wainua |
| Aurinia Pharma U.S., INC. | $337.86 | 2022-2024 | Lupkynis |
| Novo Nordisk INC | $309.90 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Vifor Pharma, INC. | $259.79 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $236.58 | 2020-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $216.24 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $174.13 | 2022-2024 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $172.51 | 2021-2024 | Onpattro, Givlaari |
| Glaxosmithkline, LLC. | $153.11 | 2020-2024 | Benlysta, Jesduvroq |
| Corcept Therapeutics | $117.99 | 2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $112.25 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $105.88 | 2020-2024 | |
| Opko Pharmaceuticals, LLC | $91.98 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.